Pharmaceutical company Neuraxpharm Group reported on Wednesday the formation of Neuraxpharm Portugal in Lisbon, expanding its operations in Southern Europe.
Neuraxpharm Portugal will be part of the company's Southern European Region that comprises Italy, Spain and now Portugal.
Through the new subsidiary, Neuraxpharm will leverage its industry networks and central nervous system (CNS) expertise to make its extensive portfolio available to patients. It is planning the first commercial launch in December this year with a probiotic product.
The company aims to build its position as a CNS specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market.
Javier Mercadé, the general manager of Italy and Spain, was appointed as head of Southern Region earlier this year and Teng Dias has been named as commercial director of the Neuraxpharm Portugal business.
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers